Although Safe, Tecovirimat Proves Ineffective for Treating Clade II Mpox

More data from the STOMP trial presented at CROI 2025, held in San Francisco, confirms that tecovirimat does not reduce the time to clinical resolution of clade II mpox lesions or improve pain among adults.